AGM/EGMMay 27, 2026, 04:08 PM
Arbutus Biopharma Shareholders Approve 2026 Share Plan, Elect Directors
AI Summary
Arbutus Biopharma Corporation held its 2026 Annual General and Special Meeting of Shareholders, where several key proposals were approved. Shareholders adopted the 2026 Omnibus Share and Incentive Plan, authorizing the issuance of 16,300,000 common shares. Additionally, all five director nominees were elected, executive compensation was approved on an advisory basis, and Ernst & Young LLP was appointed as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Highlights
- Shareholders approved the 2026 Omnibus Share and Incentive Plan, authorizing 16,300,000 common shares.
- The 2026 Plan was approved with 138,877,189 votes For, 7,408,185 Against, and 188,253 Abstained.
- All five director nominees were elected, with votes ranging from 126,670,273 to 139,299,405 For.
- Executive officer compensation was approved on a non-binding advisory basis with 137,629,207 votes For.
- Ernst & Young LLP was approved as the independent auditor for 2026 with 164,372,596 votes For.
Price Impact
More from ABUS